50 results about "CxC chemokine" patented technology

The invention discloses a human immunodeficiency virus (HIV) affinity adsorption column, comprising a column body and at least one activated affinity microsphere located in the column body, wherein the activated affinity microsphere is connected with a human immunodeficiency virus affinity protein, and the affinity protein can be bound with human immunodeficiency virus. The affinity protein comprises a main receptor CD4 molecule, a gp120 antibody, an auxiliary receptor CXC chemokine receptor 4 (CXCR-4) and a CC chemokine receptor 5 (CCR-5). The affinity microsphere may be a glass microsphere with the size of 1mm, a chitosan crosslinking microsphere with the diameter more than 500 microns, or a gluosan microsphere. The human immunodeficiency virus affinity adsorption column disclosed by the invention is applicable for eliminating the human immunodeficiency virus in the blood of HIV patients, and relieving and treating the immunodeficiency syndrome of HIV patients; and compared with the traditional treatment methods, the immunoadsorption column has high safety, good specificity, small toxic or side effects and good operation simplicity.

The present invention generally relates to the design, preparation, derivation, and use of mimetics of CXC chemokines (CXCL1-CXCL17) in the prevention, treatment, and ameliorization of a wide variety of diseases and disorders. Generally speaking, this invention is directed to the design, synthesis, and use of chemokine analogs which bind to CXC chemokine receptors CXCR1-CXCR7, such that the analogs can be designed to affect the activity of the receptor, either as an agonist or an antagonist. The analogs can be useful for treating a wide variety of diseases and disorders, and can also serve as an adjunct to the treatment of a variety of diseases and disorders.

The present invention provides novel polypeptide sequences, methods for production thereof and uses thereof for novel ELR-CXC chemokine receptor agonists and antagonists.

The invention provides an ELISA (Enzyme-linked Immunoassay Assay) plate and kit for predicting ALI (Acute Lung Injury)/ARDS (Acute Respiratory Distress Syndrome) and assessing prognosis of the ALI/ARDS. The ELISA plate comprises a solid phase carrier which is provided with a monoclonal antibody of bone morphogenetic protein 15, a monoclonal antibody of CXC chemokine ligand 16, a monoclonal antibody of CXC chemokine receptor 3, a monoclonal antibody of interleukin-6, a monoclonal antibody of nephroblastoma overexpression genes, a monoclonal antibody of insulin-like growth factor binding protein 4, a monoclonal antibody of interleukin-5, a monoclonal antibody of interleukin 5 receptor, a monoclonal antibody of interleukin 22 receptor binding protein, a monoclonal antibody of leptin, a monoclonal antibody of macrophage inflammatory protein-1D, a monoclonal antibody of orexin B, a monoclonal antibody of CC type chemokine receptor 2, a monoclonal antibody of transforming growth factor-beta5 and blank control holes. The ELISA plate and kit can achieve accurate results and are simple to operate.

The invention relates to a reagent kit for the early warning and the diagnosis of severe hepatitis and hepatic failure and a preparation method thereof, which belong to the medical detection reagent. The reagent kit comprises an enzyme-linked immunosorbnent assay (ELISA) plate which is coated with a CXC chemokine ligand-10 (CXCL10)-resistant monoclonal antibody. The ELISA plate is prepared through the following steps that: (1) the CXCL10 monoclonal antibody is diluted by acetate buffer solution with the pH value of 4.6 until the concentration of the CXCL10 monoclonal antibody is 2 micrograms per milliliter; (2) the CXCL10 monoclonal antibody solution is filled into reaction holes of the blank chemical luminous ELISA plate to be statically placed for 12 hours at the temperature of 4 DEG C; (3) liquid inside the reaction holes is removed, and each reaction hole is adequately washed by washing liquor and is dried; and (4) the ELISA plate is sealed and then is dried. The reagent kit has the advantages that the sensitivity and the accuracy are high, the repeatability is good, the minimum detection limit can be 0.1pg/mL, the variation coefficient range is 6.5%-13.1%, and early warning and diagnosis can be provided for the severe hepatitis and the hepatic failure so as to provide sufficient time for doctors and patients to take reasonable prevention and treatment measures.

The invention relates to methods of identifying ligands, and inhibitors (e.g., antagonists) or promoters (e.g., agonists) of receptor function, including methods in which host cells comprising a nucleic acid encoding a CXCR3 or variant thereof are used in an assay to identify and assess the efficacy of ligands, inhibitors or promoters. Inhibitors and promoters of receptor function can be used to modulate receptor activity, permitting selective inhibition of lymphocyte function, particularly of effector cells such as activated T lymphocytes and NK cells for therapeutic purposes.

Disclosed are techniques capable of objectively and specifically evaluating various mental or physical conditions, of which evaluation was conventionally possible only by subjective symptom-dependent methods, such as stress and fatigue. Specifically disclosed are a stress or fatigue indicating agent including at least two factors selected from the group consisting of IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, IL-18, Eotaxin, FGF basic, G-CSF, GM-CSF, IFN-γ, IFN-α, IP-10, MCP-1, MIP-1α, MIP-1β, PDGF-BB, RANTES, TNF-α, VEGF, CSF-2, TGF-β, neurotrophin 5, MCP-3, β-2-microglobulin, angiotensin II, CSF-3, CXC chemokine ligand 1, CXC chemokine ligand 5 and HGF; an agent for testing stress or fatigue including at least two molecules selected from the group consisting of molecules specifically recognizing the factors, respectively; a method of measuring stress or fatigue with the test agent; and an indicating agent for evaluating the intensity of mental conditions or disorders, including at least two factors selected from the factor group, wherein each of the factors is weighted.

The present invention provides antibodies which bind to CXC chemokine receptor (4) (CXCR4) and which do not induce significant apoptosis of CXCR4 expressing cells. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.

This application discloses a novel process for the preparation of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds, which have utility, for example, in the treatment of CXC chemokine-mediated diseases, and intermediates useful in the synthesis thereof.

Provided is a method for preventing or treating a peripheral arterial occlusive disease (PAOD), including administering to a subject a CXC chemokine ligand 5 (CXCL5) antagonist in an effective amount. Also provided is a method for preventing or treating a peripheral ischemic tissue or a tissue damaged by peripheral ischemia through inhibition of CXCL5 to enhance angiogenesis, which may lead to an acceleration of wound healing.

Described herein is the use of a modified human chemokine, GS-CXCL8_(3-72)K11R/G31P or G31P in the treatment of a number of cancers, including but by no means limited to prostate cancer, liver cancer and melanoma.

Provided is a method for treatment of liver cancer and inhibition of metastasis with CXCR4-targeted nanoparticle. A CXCR4 antagonist is used as a targeting molecule to modify a lipid carrier for the formation of nanoparticle carrying an anti-angiogenesis drug or an anti-angiogenic nucleotide. Such nanoparticle can enhance the accumulation and uptake of the drug and nucleotide in liver cancer cells as well as sensitize the liver cancer cells to treatment of said drug and nucleotide, providing a synergistic suppression of angiogenesis and tumor progression. Furthermore, the CXCR4-targeted nanoparticle can effectively inhibit metastasis of liver cancer. The pharmaceutical composition is an injectable composition; hence, is suitable for clinical application for the treatment of liver cancer.

Provided are compositions comprising one of more molecules that specifically bind to CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2) and methods for treating and improving the symptoms of pathologic bone loss in a subject by administering to the subject a therapeutically effective amount of such compositions.